Legend Biotech (NASDAQ:LEGN) Price Target Cut to $25.00 by Analysts at Oppenheimer

Posted by Stanley Muller on Nov 11th, 2026

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price lowered by equities researchers at Oppenheimer from $40.00 to $25.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “market perform” rating on the stock. Oppenheimer‘s target price points to a potential upside of 30.16% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. UBS Group reissued a “buy” rating and set a $65.00 price objective on shares of Legend Biotech in a report on Monday, September 28th. JPMorgan Chase & Co. lowered their target price on shares of Legend Biotech from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Barclays dropped their target price on shares of Legend Biotech from $68.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday. TD Cowen cut their price target on shares of Legend Biotech from $29.00 to $24.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Finally, Benchmark reissued a “buy” rating on shares of Legend Biotech in a research report on Tuesday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Legend Biotech presently has an average rating of “Moderate Buy” and a consensus target price of $50.85.

Check Out Our Latest Stock Analysis on LEGN

Legend Biotech Price Performance

Shares of NASDAQ LEGN traded down $1.20 during midday trading on Wednesday, hitting $19.21. 1,496,319 shares of the company’s stock were exchanged, compared to its average volume of 2,406,237. Legend Biotech has a twelve month low of $16.24 and a twelve month high of $37.50. The company has a market cap of $3.72 billion, a PE ratio of -76.86 and a beta of 0.55. The firm’s fifty day simple moving average is $19.75 and its 200-day simple moving average is $22.12.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $359.50 million during the quarter, compared to the consensus estimate of $361.46 million. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.05) earnings per share. Equities analysts anticipate that Legend Biotech will post -0.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Carlos E. Santos sold 5,430 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the sale, the chief financial officer owned 14,246 shares in the company, valued at $130,208.44. This represents a 27.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the firm’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total transaction of $258,920.20. Following the transaction, the director directly owned 52,731 shares in the company, valued at $498,835.26. The trade was a 34.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.02% of the company’s stock.

Institutional Investors Weigh In On Legend Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. acquired a new stake in shares of Legend Biotech during the second quarter worth about $55,307,000. Squarepoint Ops LLC increased its position in Legend Biotech by 60.4% in the 2nd quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after acquiring an additional 289,772 shares during the period. Renaissance Technologies LLC increased its position in Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock valued at $9,439,000 after acquiring an additional 119,000 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Legend Biotech by 343.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock valued at $7,361,000 after acquiring an additional 315,176 shares during the period. Finally, Tidal Investments LLC raised its stake in Legend Biotech by 34.0% during the 2nd quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock valued at $6,945,000 after acquiring an additional 61,023 shares during the last quarter. 70.89% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Legend Biotech

Investors following LEGN have been watching these headlines:

Positive Sentiment: CARVYKTI net trade sales rose 36% year over year to about $710 million in Q3. Legend also reported adjusted EPS of $0.14, above the $0.01 consensus, while revenue grew 32% to $359.5 million. Legend Biotech Q3 results
Positive Sentiment: The company said it is targeting adjusted profitability in 2026 and received FDA clearance to begin an investigational in-vivo CAR-T therapy trial, adding a potential pipeline opportunity. Profitability target and margin outlook
Negative Sentiment: Reports said investors were concerned about decelerating U.S. demand for CARVYKTI. Legend also revised its Q4 gross-margin outlook to the high-50% range, raising near-term profitability concerns. Article on CARVYKTI demand concerns

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.